a Three regiodivergent Baeyer-Villiger mono-oxygenases (enantioselectively) oxidized a series of cyclic a,b-unsaturated ketones into (chiral) either enol-lactones or ene-lactones. An easy-to-use and efficient biocatalytic process based on a host-microorganism deprived of unwanted activities (knock-out mutant) was developed to enable the exclusive synthesis of unsaturated lactones.
like intermediate that undergoes the same type of rearrangement as in chemical BV reactions. Besides BV oxidation of ketones, the enzymes are able to oxygenate sulfur, selenium, nitrogen, boron atoms and, much more exceptionally, epoxidize the double bond. The main difference when compared to chemical reagents comes from the general lack of activity against a,b-unsaturated ketones. 9, 11 To the best of our knowledge, the only unambiguous mention of such a reaction being enzymatically catalyzed was reported in 1996: the oxidation of 5-hexyl-2-cyclopenten-1-one by pure cyclopentanone monooxygenase from Comamonas sp. NCIMB 9872 (CPMO Coma ). 12 Since no other publications have described BVMO-mediated enol or ene-lactone formation, 13 thus syntheses of these compounds remain challenging. 5,6a We confirmed here that (asymmetric) enzymatic BV oxidation of cyclic enones is possible and offers a promising route for the synthesis of (chiral) unsaturated lactones. We report for the first time the BV oxidation of a series of a,b-unsaturated ketones using CPMO Coma and two new BVMOs. The enzymes displayed a complementary regioselectivity and enantioselectivity, leading to either the corresponding conjugated ene-lactones or enol-lactones. An easy-to-use and efficient biocatalytic process based on a host-microorganism deprived of unwanted endogenous reductase activity was also developed.
BVMO Ocean , from Oceanicola batsensis DSM 15984, and BVMO Parvi , from Parvibaculum lavamentivorans DSM 13023, were selected in the course of screening of sixty putative bacterial Type I BVMOs chosen from genomic databases to cover the genomic diversity as well as possible.
14 The genes were heterologously expressed in E. coli strain BL21(DE3). 15 The activities of the corresponding enzymes were assayed against various ketone substrates by monitoring NADPH depletion in crude extracts. Only two extracts displayed activity against Enol-lactones 3a-c were exclusively produced with E. coli BL21(DE3) containing BVMO Parvi . They resulted from the oxygen atom insertion between the carbonyl group and the double bond as observed in chemical BV oxidation. However the epoxidation of the double bond, a frequent side-reaction that has prevented chemical BV oxidation being used for the synthesis of ene-lactones 3a-c, 4, 8 was not observed.
Construction of an engineered strain deprived of ene-reductase activity: large amounts of saturated ketones or corresponding saturated lactones were formed with both strains (Table 1) , lessening the interest in these microbiological transformations. The presence of cycloalkenone reductase activity in E. coli BL21(DE3) was confirmed by whole-cell biotransformation of 1a-c (see ESI †) while unsaturated lactones were not hydrogenated. The reductase required nicotinamide cofactors, with a preference for NADPH as type I BVMOs. The literature 11, 17 suggested that NemA reductase is a good candidate and its contribution to cycloalkenone hydrogenation was confirmed when we tested the knock-out mutant BW25113DnemA obtained from the Keio collection. 18 An E. coli BL21(DE3) expression strain without active enone reductase was engineered by exchanging nemA gene for DnemA knockout cassette from BW25113DnemA using bacteriophage P1 transduction. 19 The newly engineered BL21(DE3)DnemA strain was then used as a host for the overexpression of BVMO Ocean and BVMO Parvi .
Preparative biotransformations using newly constructed strains: biotransformations carried out with the new biocatalysts, BL21(DE3)DnemA strains expressing BVMO Ocean and BVMO Parvi , showed the almost complete abolition of the saturated lactone formation (Table 1) . These experiments clearly demonstrated that the knock-out strains producing BVMOs were suitable for large scale BV oxidation of cycloalkenones. 20 Widening the range of substrates: whole cell biotransformations of methyl substituted cycloalkanones 5a-c and cycloalkenones 5d-g were performed (Scheme 2). All saturated ketones 5a-c were transformed by both enzymes but a strong disparity, depending on substrate and enzyme, was observed in enantio-or enantiotoposelectivity as shown in Tables 2 and 3 . The results obtained with BVMO Ocean were very close to those reported with the well-known CHMO Acineto , this was consistent with their high sequence identity (58%). However, even though they have an equivalent identity (53%), BVMO Parvi and CPMO Coma differed in enantioselectivity (see ESI †).
The most surprising behavior arose from the reactivity of both new enzymes with substituted cycloalkenones. Only BVMO Parvi was able to transform ketones 5d-f and afford exclusively enollactones 6d-f in good yields (Table 2) as for experiments with 1a-c. Moreover, highly optically active enol-lactone (R)-6g was obtained from 5g (enantiomeric ratio E = 37), highlighting for the first time the BVMO capacity to catalyze enantioselective enol-lactone formation. On the other hand, 5g was the unique methylated enone of the series to act as a substrate of BVMO Ocean , suggesting a strong sensitivity of the enzyme towards the double bond substitution. 5g was oxidized into the conjugated enelactone 7g with the same regioselectivity as the non-substituted enones. A high enantioselectivity was also observed (E = 31), leading to the preferential formation of the (R)-enantiomer in good yield (Table 3) .
The same experiments were performed with a similarly constructed knock-out E. coli strain producing CPMO Coma and revealed a behavior of this enzyme identical to that of BVMO Parvi (see Table 4 and ESI †). This outcome highlighted the advantage of our knock-out E. coli strain since in a previous published study based on an unmodified strain, any eventual BV activity of CPMO Coma on cyclohexenones was totally masked by reductase activity. 21 In contrast, we confirmed, as previously suggested, 11 that CHMO Acineto was unable to use cyclohexenones as substrates although sharing 58% sequence identity with BVMO Ocean . Thus the three enzymes displayed the same enantiopreference but a regiodivergence was observed between BVMO Ocean on one hand and CPMO Coma and BVMO Parvi on the other hand. The protein sequences show a low similarity (35-40%) between these two groups, it is likely that their particular activities towards enones come from a very subtle variation in the aminoacid arrangement that will require comparisons with a larger number of enzymes with similar activities before being understood.
In conclusion, a long standing gap in the chemistry of BVMOs has been filled. We confirmed that this family of enzymes is able to convert without exception the same type of compounds as peracids do. The two original activities discovered on cyclic a,b-unsaturated ketones associated with a strategy based on knockout mutant strains allowed easy access to enol-lactones and conjugated ene-lactones, expanding the toolbox of the synthetic chemist. The range of substrates still remains to be explored more widely and the molecular reasons for the rareness of BVMO mediated reactivity towards enones need to be understood. Nevertheless, these preliminary studies, particularly as far as enantioselectivity is concerned, pave the way toward valuable new enantiopure unsaturated synthons.
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c Enantiomeric ratios were calculated from three couples of substrate and product ees. a Preparative biotransformations were carried out at 3 mM scale into 2L flasks. b Yields were determined by GC analysis using internal standard.
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